A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk

Giuseppe Derosa, Amedeo Mugellini, Rosa M Pesce, Angela D'Angelo, Pamela Maffioli, Giuseppe Derosa, Amedeo Mugellini, Rosa M Pesce, Angela D'Angelo, Pamela Maffioli

Abstract

Aim: To evaluate the relevance of adding acetylsalicylic acid (ASA) in primary prevention in subjects with type 2 diabetes mellitus.

Methods: 213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B). We assessed at baseline, at the end of Phase A, and at the end of Phase B the levels of some new emerging biomarkers of cardiovascular risk including: high sensitivity C-reactive protein (Hs-CRP), adiponectin (ADN), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), myeloperoxidase (MPO), soluble CD40 ligand (sCDL40).

Results: Compared to baseline, at the end of Phase A, patients treated with amlodipine 5 mg + ASA 100 mg showed a statistically significant reduction of Hs-CRP (-15.0%), TNF-α (-21.7%), MPO (-9.7%), and sCDL40 (-15.7%), and a statistically significant increase of ADN (+15.0%). These values were significantly better than the ones obtained with amlodipine alone. Similarly, at the end of Phase B, amlodipine 10 mg + ASA significantly lowered Hs-CRP (-18.8%), TNF-α (-15.0%), MPO (-9.2%), and sCDL40 (-20.0%) and increased ADN (+11.8%), with a better effect compared to amlodipine alone.

Conclusion: All biomarkers considered were significantly improved by ASA addition. These data suggest that the use of ASA in primary prevention could be useful in patients with type 2 diabetes mellitus and hypertension.

Trial registration: ClinicalTrials.gov: NCT02064218.

Figures

Fig. 1
Fig. 1
Study design.

References

    1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–321. doi: 10.1016/j.diabres.2011.10.029.
    1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–444. doi: 10.2337/diacare.16.2.434.
    1. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA, et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database. Diabetologia. 2006;49(12):2859–2865. doi: 10.1007/s00125-006-0493-z.
    1. Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M, et al. Study Group. Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the study: a cluster randomized trial. Diabetes Care. 2013;36(9):2566–2572. doi: 10.2337/dc12-1781.
    1. . Accessed Jan 2015
    1. American Diabetes Association Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S1–S94.
    1. Sirois C, Couture J, Grégoire JP. Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks? Ther Adv Drug Saf. 2012;3(5):213–226. doi: 10.1177/2042098612451267.
    1. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141. doi: 10.1001/jama.2008.623.
    1. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. doi: 10.1136/bmj.a1840.
    1. Derosa G, D’Angelo A, Mugellini A, Pesce RM, Fogari E, Maffioli P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr Med Res Opin. 2012;28(9):1435–1445. doi: 10.1185/03007995.2012.717527.
    1. Rydén L, Standl E, Bartnik M, VandenBerghe G, Betteridge J, deBoer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J. 2007;28(1):88–136.
    1. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45(12):2136–2141.
    1. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–946. doi: 10.1038/90984.
    1. Zhang M, Tracey K. The cytokine handbook. 3. San Diego: Academic Press; 1988.
    1. Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP., Jr Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom. 2004;61:35–39. doi: 10.1002/cyto.b.20021.
    1. Morishita K, Kubota N, Asano S, Kaziro Y, Nagata S. Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem. 1987;262(8):3844–3851.
    1. Graf D, Korthäuer U, Mages HW, Senger G, Kroczek RA. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol. 1992;22(12):3191–3194. doi: 10.1002/eji.1830221226.
    1. Winer BJ. Statistical principles in experimental design. 2. New York: McGraw-Hill; 1971.
    1. Vaucher J, Marques-Vidal P, Waeber G, Vollenweider P. Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus study) Cytokine. 2014;66(2):95–100. doi: 10.1016/j.cyto.2014.01.003.
    1. Rosiak M, Postula M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Czlonkowski A, et al. Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study. Cardiol J. 2013;20(5):545–551. doi: 10.5603/CJ.2013.0045.
    1. Takahashi Y, Nishida Y, Nakayama T, Asai S. Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. Cardiovasc Diabetol. 2013;12:87. doi: 10.1186/1475-2840-12-87.
    1. Kaplon-Cieslicka A, Postula M, Rosiak M, Peller M, Kondracka A, Serafin A, et al. Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. Cardiovasc Diabetol. 2014;13:112. doi: 10.1186/s12933-014-0112-0.
    1. Irons BK, Trujillo A, Seifert CF, Simoni JS, Doctolero S, Abo-Salem E, et al. Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. J Cardiovasc Pharmacol Ther. 2013;18(5):427–432. doi: 10.1177/1074248413489772.
    1. Tanaka M, Nishimura R, Nishimura T, Kawai T, Meguro S, Irie J, et al. Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients. Diabetol Metab Syndr. 2014;6:56. doi: 10.1186/1758-5996-6-56.
    1. Khan BV, Merchant N, Rahman ST, Ahmad M, Parrott JM, Umar K, et al. Changes in central aortic pressure, endothelial function and biomarkers in hypertensive african-americans with the cardiometabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan. Cardiorenal Med. 2013;3:221–231. doi: 10.1159/000355136.
    1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235. doi: 10.1038/newbio231232a0.
    1. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974;26(1):33–67.
    1. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180–186.
    1. Hennekens CH, Sechenova O, Hollar D, Serebruany VL. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther. 2006;11(3):170–176. doi: 10.1177/1074248406292263.
    1. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17(3–4):317–327. doi: 10.1016/0049-3848(80)90066-3.
    1. Weissmüller T, Campbell EL, Rosenberger P, Scully M, Beck PL, Furuta GT, et al. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest. 2008;118(11):3682–3692. doi: 10.1172/JCI35874.
    1. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA. 1995;92(21):9475–9479. doi: 10.1073/pnas.92.21.9475.
    1. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996;274(5291):1383–1385. doi: 10.1126/science.274.5291.1383.
    1. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 2009;183(3):2089–2096. doi: 10.4049/jimmunol.0900477.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner